SARcode's lead investigational molecule, SAR 1118, demonstrated promising results in a Phase II study of dry eye disease, according to data presented at this year's Association for Research in Vision and Ophthalmology (ARVO) meeting
SARcode's lead investigational molecule, SAR 1118, demonstrated promising results in a Phase II study of dry eye disease, according to data presented at this year's Association for Research in Vision and Ophthalmology (ARVO) meeting.
The small molecule integrin antagonist inhibits T-cell medicated inflammation and can also be used to treat diabetic macular oedema.
Dr Charles Semba et al., SARcode Corporation, Brisbane, California, USA, conducted a randomized, placebo-controlled, multi centre study on 230 patients with dry eye disease. The Ocular Surface Disease Index (OSDI) was used to evaluate visual-related function. SAR 1118, the potent novel small molecule lymphocyte function-associated antigen, was topically administered to all patients.
It was concluded that SAR 1118 was safe and well tolerated amongst dry eye patients. There were no serious ocular effects recorded, most of them being transient and not related to the administration of SAR 1118. Corneal staining was reduced over 12 weeks, tear production increased after 2 weeks and visual-related functions vastly improved.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.